【Abstract】 Objective To investigate the clinical value of quantitative detection of human papillomavirus (HPV) E6/E7 mRNA in cervical intraepithelial neoplasia and cervical cancer screening. Methods 224 highrisk human papillomavirus (HRHPV) patients diagnosed in our hospital from June 2015 to June 2017 were selected. According to the pathological diagnosis, 90 cases were negative for intraepithelial lesion (NILM), 75 cases were cervical intraepithelial neoplasia (CIN) Ⅰ, 24 cases were CIN Ⅱ, 21 cases were CIN Ⅲ and 14 cases were cervical cancer. The positive rate and expression level of HPVE6 / E7 mRNA in cervical exfoliated cells were detected by bDNA technique. Then positive rates and expression levels of HPVE6 / E7 mRNA in different grades of thinprep cytologic test (TCT) were compared. Results The positive rate of HPVE6 / E7 mRNA decreased gradually in cervical cancer group (P＜0.05). The expression of HPVE6 / E7 mRNA was also gradually decreased in cervical cancer group, CIN Ⅰgroup, CIN Ⅱgroup, CIN Ⅲ group, and NILM group (P＜0.05), while no difference was found in the comparison of CIN Ⅰgroup and CIN Ⅱgroup, and the comparison of CIN Ⅰgroup and NILM group (P＞0.05). The positive rate of HPV E6/E7 mRNA in abnormal cytologic result groups including high grade squamous intraepithelial lesion (HSIL), low grade squamous intraepithelial lesion (LSIL), atypical squamous cell carcinoma (ASC), no squamous intraepithelial lesion (NSIL) were significantly lower than that in cervical cancer group respectively (P＜0.05). The expression of HPV E6/E7 mRNA in abnormal cytological result groups (include HSIL, LSIL, ASC, NSIL) were significantly lower than that in cervical cancer group respectively (P＜0.05). Conclusion The HPV E6 / E7 mRNA test can be used to screen for cervical cancer and highgrade CIN, which can be used as a molecular marker for precancerous lesions and cervical cancer screening.